What are the indications for chemotherapy in patients with undifferentiated pleomorphic sarcoma of the breast?

Chemotherapy Indications for Undifferentiated Pleomorphic Sarcoma of the Breast

For localized, resectable undifferentiated pleomorphic sarcoma (UPS) of the breast, adjuvant chemotherapy with anthracycline-based regimens (doxorubicin with or without ifosfamide) should be strongly considered when tumors are ≥5 cm, with the greatest benefit demonstrated in tumors 10-15 cm in size. 1

Treatment Algorithm by Disease Stage

Localized/Resectable Disease

Surgical resection is the primary treatment, but chemotherapy decisions depend critically on tumor size:

• Tumors <5 cm: Adjuvant chemotherapy shows no survival benefit and should generally be avoided 1

• Tumors 5-10 cm: Adjuvant chemotherapy shows a trend toward improved survival (87% vs 80% 5-year OS, p=0.06) - consider in patients with good performance status 1

• Tumors 10-15 cm: Adjuvant chemotherapy provides significant survival benefit (79.5% vs 66.8% 5-year OS, p=0.003) and should be strongly recommended 1

• Tumors ≥15 cm: Adjuvant chemotherapy shows a trend toward benefit (60.7% vs 49.5% 5-year OS, p=0.08) - consider despite marginal statistical significance given poor baseline prognosis 1

The preferred regimen is anthracycline-based chemotherapy (doxorubicin ± ifosfamide), as this is the standard first-line treatment for soft tissue sarcomas per NCCN and ESMO guidelines 2, 3. Multi-agent chemotherapy with adequate-dose anthracycline-ifosfamide may be particularly appropriate when tumor response could improve surgical outcomes 3.

Advanced/Metastatic Disease

First-line treatment: Anthracycline-based chemotherapy (doxorubicin) is the standard of care 2, 3. Multi-agent regimens with doxorubicin-ifosfamide should be considered when tumor response is needed and performance status is good 3.

Second-line and beyond (in order of preference based on evidence quality):

1. Gemcitabine-docetaxel: Specifically effective in UPS per randomized trial data, though toxicity is higher with combination therapy 3

2. Trabectedin: Approved for second-line treatment with demonstrated efficacy across sarcoma subtypes 3

3. Pazopanib: For non-adipogenic sarcomas (which includes UPS) in second and further lines 2, 3

4. Pembrolizumab: Specifically listed for UPS with high tumor mutational burden (≥10 mutations/megabases) after progression on prior therapy 2

5. Eribulin: Though one case report showed progression on eribulin in breast UPS 4, it remains an option based on broader sarcoma data, particularly for liposarcomas

Critical Caveats

Neoadjuvant chemotherapy may be considered for large tumors (>5 cm) to facilitate surgical resection, as demonstrated in a case report where epirubicin-ifosfamide enabled successful extended resection of a 9.5 cm breast UPS 5. This patient remained disease-free at 44 months despite high-risk features.

Breast location specificity: While UPS of the breast is exceedingly rare, the treatment principles follow general soft tissue sarcoma guidelines 2, 3. The breast location does not alter chemotherapy indications, which are primarily driven by tumor size, grade (UPS is by definition high-grade), and metastatic status.

Poor prognosis with metastatic disease: Response rates to conventional chemotherapy are only 27-33% 6, and metastatic breast UPS carries particularly poor prognosis, as illustrated by a case with lung and bone metastases where the patient died 4 months post-mastectomy despite treatment 4.

Emerging therapies: Immune checkpoint inhibitors combined with doxorubicin show promising response rates in recent trials 6, and UPS is specifically mentioned as responsive to pembrolizumab in guidelines 2. Consider clinical trials when available.